Sunday, February 5, 2023
manilastandard.net
ADVERTISEMENT
  • About
  • News
    • Top Stories
    • National
    • World News
    • Pinoy Abroad
    • Features
  • Opinion
    • Editorial
    • Columns
    • Soundbytes
  • LGUs
    • NCR
    • Luzon
    • Visayas
    • Mindanao
  • Business
    • Corporate
    • Economy & Trade
    • Stocks
    • Money
    • Agri & Mining
    • Power & Tech
    • IT & Telecom
  • Sports
    • Basketball
    • Volleyball
    • Fightsports
    • Active
    • Sports Plus
    • One Championship
    • Columns
  • Entertainment
    • TV & Movies
    • Celebrity Profiles
    • Music & Concerts
    • Digital Media
    • Columns
  • Lifestyle
    • Food
    • Culture & Media
    • Fashion
    • Health and Home
    • Leisure
    • Shopping
    • Columns
  • Others
    • Pets
    • Pop.Life
      • Newsmakers
      • Hangouts
      • A-Pop
      • Post Its
      • Performances
      • Malls & Bazaars
      • Hobbies & Collections
    • Technology
      • Gadgets
      • Computers
      • Business
      • Tech Plus
    • MS ON THE ROAD
      • Sedan
      • SUV
      • Truck
      • Bike
      • Accessories
      • Motoring Plus
      • Commuter’s Corner
    • Home & Design
      • Residential
      • Commercial
      • Construction
      • Interior
    • Spotlight
    • Gallery
      • Photos
      • Videos
    • Events
      • Seminars
      • Exhibits
      • Community
    • Biyahero
      • Travel Features
      • Travel Reels
      • Travel Logs
  • Advertise with Us
No Result
View All Result
  • About
  • News
    • Top Stories
    • National
    • World News
    • Pinoy Abroad
    • Features
  • Opinion
    • Editorial
    • Columns
    • Soundbytes
  • LGUs
    • NCR
    • Luzon
    • Visayas
    • Mindanao
  • Business
    • Corporate
    • Economy & Trade
    • Stocks
    • Money
    • Agri & Mining
    • Power & Tech
    • IT & Telecom
  • Sports
    • Basketball
    • Volleyball
    • Fightsports
    • Active
    • Sports Plus
    • One Championship
    • Columns
  • Entertainment
    • TV & Movies
    • Celebrity Profiles
    • Music & Concerts
    • Digital Media
    • Columns
  • Lifestyle
    • Food
    • Culture & Media
    • Fashion
    • Health and Home
    • Leisure
    • Shopping
    • Columns
  • Others
    • Pets
    • Pop.Life
      • Newsmakers
      • Hangouts
      • A-Pop
      • Post Its
      • Performances
      • Malls & Bazaars
      • Hobbies & Collections
    • Technology
      • Gadgets
      • Computers
      • Business
      • Tech Plus
    • MS ON THE ROAD
      • Sedan
      • SUV
      • Truck
      • Bike
      • Accessories
      • Motoring Plus
      • Commuter’s Corner
    • Home & Design
      • Residential
      • Commercial
      • Construction
      • Interior
    • Spotlight
    • Gallery
      • Photos
      • Videos
    • Events
      • Seminars
      • Exhibits
      • Community
    • Biyahero
      • Travel Features
      • Travel Reels
      • Travel Logs
  • Advertise with Us
No Result
View All Result
manilastandard.net
No Result
View All Result
Home News National

Johnson & Johnson COVID-19 vaccine candidate demonstrates robust protection in pre-clinical studies

Manila StandardbyManila Standard
July 30, 2020, 10:05 pm
in National
Reading Time: 3 mins read
A A
Share on FacebookShare on TwitterShare on Email

Johnson & Johnson announced that its lead vaccine candidate for COVID-19 elicited a robust immune response as demonstrated by “neutralizing antibodies” in pre-clinical studies.

The data, published in Nature, showed that the company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine successfully prevented subsequent infection and completely protected the lungs from the SARS-CoV2 virus in non-human primates (NHPs) during the pre-clinical study.

“We are excited to see these pre-clinical data because they show our SARS-CoV-2 vaccine candidate generated a strong antibody response and provided protection with a single dose,” said vice chairman of the executive committee and Chief Scientific Officer Paul Stoffels.

“The findings give us confidence as we progress our vaccine development at and upscale manufacturing in parallel, having initiated a Phase 1/2a trial in July with the intention to move into Phase 3 trials in September,” he added.

The pre-clinical studies were conducted by researchers from Beth Israel Deaconess Medical Center (BIDMC) in collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson and others as part of its ongoing collaboration to accelerate the development of a SARS-CoV-2 vaccine.

ADVERTISEMENT

In the studies, researchers first immunized the NHPs with a panel of vaccine prototypes, and then challenged them with SARS-CoV-2 infection.

The scientists found that, of seven vaccine prototypes tested in the study, Ad26.COV2.S elicited the highest levels of neutralizing antibodies to SARS-CoV-2.

The level of antibodies correlated with the level of protection, confirming previous observations and suggesting that they could be a potential biomarker for vaccine-mediated protection.

The six NHPs that received a single immunization with Ad26.COV2.S showed no detectable virus in the lower respiratory tract after exposure to SARS-CoV-2, and only one of six showed very low levels of the virus in a nasal swab at two time points.

Dan Barouch, director of the Center for Virology and Vaccine Research at BIDMC and the Ragon Institute, said “the pre-clinical data, generated in partnership with the Johnson&Johnson team, highlights the potential of this SARS-CoV-2 vaccine candidate. Moreover, the data suggest that antibody levels may serve as a biomarker for vaccine-mediated protection.”

The robust Janssen COVID-19 clinical trial program, including the Phase 1/2a clinical trials and the Phase 3 clinical trial program, will evaluate both one- and two-dose regimens of Ad26.COV2.S in parallel studies.

The Phase 1/2a trial will evaluate the safety, reactogenicity (expected reactions to vaccination, such as swelling or soreness), and immunogenicity of Ad26.COV2.S in over 1,000 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older.

Based on the strength of the data, a Phase 1/2a first-in-human clinical trial of the vaccine candidate, Ad26.COV2.S, in healthy volunteers, has now commenced in the United States and Belgium.

Plans are also underway for a Phase 2a study in the Netherlands, Spain and Germany and a Phase 1 study in Japan.

As the company plans its COVID-19 Phase 3 clinical development program, discussions are underway with partners with the objective to start a pivotal Phase 3 clinical trial of the single vaccine dose versus placebo in September, pending the interim data of the Phase 1 and 2 trials and approval of regulators.

Simultaneously, the company is also planning to start a parallel Phase 3 clinical trial of a two-dose regimen versus placebo.

Johnson & Johnson also shared that they will emphasize representation of populations that have been disproportionately impacted by the pandemic as it designs and implements its COVID-19 Phase 3 trial program.

In the United States, this would include significant representation of Blacks, Hispanic/Latinx and participants over 65 years of age.

“As we collectively battle this pandemic, we remain deeply committed to our goal of providing a safe and effective vaccine to the world. Our pre-clinical results give us reason to be optimistic as we initiate our first-in-human clinical trial, and we are excited to enter the next stage in our research and development toward a COVID-19 vaccine,” said Mathai Mammen, Global Head for Janssen Research & Development, Johnson & Johnson.

“We know that, if successful, this vaccine can be rapidly developed, produced on a large scale and delivered around the world,” Mammen added.

Tags: Beth Israel Deaconess Medical CenterCOVID-19Johnson & JohnsonMathai MammenSARS-COV2
ADVERTISEMENT
Manila Standard

Manila Standard

Related Posts

Fortun: Drug war victims had false death records

byManila Standard
February 3, 2023, 11:50 pm
0
8
Southwoods nails Seniors’ Fil golf crown

Forensic pathologist Dr. Raquel Fortun said that more victims of former President Rodrigo Duterte’s drug war had falsified death certificates....

Read more

Escudero: No tax exemption for Maharlika corp

byMacon Ramos-Araneta
February 3, 2023, 11:40 pm
0
8
Duterte floats Bicol’s Salceda, Chiz as next President

Senator Chiz Escudero said it is “bad policy” to give tax exemption to the proposed Maharlika Investment Corporation (MIC), which will manage...

Read more

JV bats for lower PhilHealth dues

byMacon Ramos-Araneta
February 3, 2023, 11:20 pm
0
8
Ejercito believes PH can repeat ‘05 SEAG feat

Senator Joseph Victor “JV” Ejercito has urged the Senate to amend Republic Act No. 11223 or the Universal Healthcare (UHC) Law...

Read more

BI nabs Japanese wanted for illegal recruitment

byVito Barcelo
February 3, 2023, 11:20 pm
0
8
Koreans top list of fugitive aliens captured by BI

The Bureau of Immigration (BI) arrested a Japanese fugitive wanted by authorities in his country for illegal recruitment and falsifying official...

Read more

PAO seeks hefty fines for erring contractors

byRio N. Araja
February 3, 2023, 11:10 pm
0
8
PAO set to transfer to new office in QC

The Public Attorney’s Office (PAO) is seeking tougher fines and penalties against developers and contractors of substandard and defective construction...

Read more

LGUs craft support plan for agrarian reform orgs

byRio N. Araja
February 3, 2023, 11:00 pm
0
8
Cruz scores Leni for meddling in farmers’ case

At least seven government agencies and nine local government units have crafted a convergence plan to benefit farmer-members of 113...

Read more

Print Edition

View More

Recent Posts

  • Sneakers for Makati : AB4.0
  • 4 China boats harass PH ship
  • NEDA vets 206 flagship plans, final list in Q1
  • Pupils prefer use of Filipino in classroom
  • PNP insists autopsy on Kian ‘honest’
  • Onion good as cash for a day in QC store
  • Gatchalian expected to breeze through appointments panel
  • All set for Army Navy Club200 Endurance Race on Feb. 11

Advertisement

Latest News

Onion good as cash for a day in QC store

byManila Standard
February 5, 2023, 1:20 am
0
8
Onion good as cash for a day in QC store

Onions, quite literally, were as good as cash if only for a day at the Japan Home Centre in Panay,...

Read more

Gatchalian expected to breeze through appointments panel

byMaricel Cruz
February 5, 2023, 1:10 am
0
8
Vergeire ‘ready’ to take DOH top job if offered

Unlike his immediate predecessor who failed to gain the nod of the Commission on Appointments (CA), newly appointed Secretary Rex...

Read more

All set for Army Navy Club200 Endurance Race on Feb. 11

byManila Standard Sports
February 5, 2023, 1:02 am
0
8
All set for Army Navy Club200 Endurance Race on Feb. 11

IT’S all systems go for the Philippines’ biggest motorsports extravaganza of 2023 – the Army Navy Club200 Endurance Race happening...

Read more

PCSO eyes 10% DST to hike funds for UHC

byAngelica Villanueva
February 5, 2023, 1:00 am
0
8
Lucky bettor wins  P162M lotto jackpot

The Philippine Charity Sweepstakes Office (PCSO) urged Congress to reduce its documentary stamp tax (DST) by one-half, or from the...

Read more

Salceda urges PBBM to name PEZA chief soon

byMaricel Cruz
February 5, 2023, 12:50 am
0
8
Salceda urges Labor, Migrant depts to lift ban on OFW

Albay Rep. Joey Sarte Salceda on Saturday called on President Marcos to appoint a permanent director-general for the Philippine Economic...

Read more

Advertisement

ADVERTISEMENT
Facebook Twitter Instagram Youtube

ABOUT US

Manila Standard

Manila Standard website (manilastandard.net), launched in August 2002, extends the newspaper’s reach beyond its traditional readers and makes its brand of Philippine news and opinion available to a much wider and geographically diverse readership here and overseas.

Digital Edition

In tone and content, the online edition mirrors the editorial thrust of the newspaper. While hewing to the traditional precepts of fairness and objectivity, MS believes the news of the day need not be staid, overly long or dry. Stories are succinct, readable and written in a lively style that has become a hallmark of the newspaper.

Download – Today’s Paper

Search

No Result
View All Result

6th Floor Universal Re Bldg., 106 Paseo De Roxas cor. Perea Street, Legaspi Village, 1226 Makati City Philippines

Trunklines: 832-5554, 832-5556, 832-5558

© 2021 Manila Standard - Designed and Developed by Neitiviti Studios.

No Result
View All Result
  • About
  • News
    • Top Stories
    • National
    • World News
    • Pinoy Abroad
    • Features
  • Opinion
    • Editorial
    • Columns
    • Soundbytes
  • LGUs
    • NCR
    • Luzon
    • Visayas
    • Mindanao
  • Business
    • Corporate
    • Economy & Trade
    • Stocks
    • Money
    • Agri & Mining
    • Power & Tech
    • IT & Telecom
  • Sports
    • Basketball
    • Volleyball
    • Fightsports
    • Active
    • Sports Plus
    • One Championship
    • Columns
  • Entertainment
    • TV & Movies
    • Celebrity Profiles
    • Music & Concerts
    • Digital Media
    • Columns
  • Lifestyle
    • Food
    • Culture & Media
    • Fashion
    • Health and Home
    • Leisure
    • Shopping
    • Columns
  • Pop.Life
    • Newsmakers
    • Hangouts
    • A-Pop
    • Post Its
    • Performances
    • Malls & Bazaars
    • Hobbies & Collections
  • Technology
    • Gadgets
    • Computers
    • Business
    • Tech Plus
  • MS ON THE ROAD
    • Sedan
    • SUV
    • Truck
    • Bike
    • Accessories
    • Motoring Plus
    • Commuter’s Corner
  • Home & Design
    • Residential
    • Commercial
    • Construction
    • Interior
  • Spotlight
  • Gallery
    • Photos
    • Videos
  • Events
    • Seminars
    • Exhibits
    • Community
  • Biyahero
    • Travel Features
    • Travel Reels
    • Travel Logs
  • Pets
  • Advertise with Us

© 2021 Manila Standard - Designed and Developed by Neitiviti Studios.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Install Manila Standard Web App

Install App